SCHEMBL5547519

SCHEMBL5547519

COC(=O)c1ccc(C(C(=O)Nc2ccc(Cl)cc2)N2CCN(C)CC2)cc1

nearest known ligand 0.60

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ADRB2 P07550 2/20 0.60
NPSR1 Q6W5P4 1/20 0.60
SMN1; SMN2 Q16637 2/20 0.57
ALDH1A1 P00352 5/20 0.54
LMNA P02545 3/20 0.52
THRB P10828 1/20 0.49
CYP1A2 P05177 1/20 0.49
CYP3A4 P08684 1/20 0.49
CYP2D6 P10635 1/20 0.49
CYP2C9 P11712 1/20 0.49
CYP2C19 P33261 1/20 0.49
MAPT P10636 3/20 0.47
TSHR P16473 2/20 0.47
GAA P10253 2/20 0.47
HPGD P15428 1/20 0.47
MEN1 O00255 1/20 0.46
KMT2A Q03164 1/20 0.46
L3MBTL1 Q9Y468 1/20 0.45
ABCB1 P08183 2/20 0.45
TP53 P04637 2/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL2686264 0.93 ADRB2 (0.53) ADRB2NPSR1SMN1; SMN2ALDH1A1LMNA
SCHEMBL2685263 0.81 MAPT (0.53) NPSR1SMN1; SMN2ALDH1A1LMNATHRB
SCHEMBL2688071 0.80 MAPT (0.51) NPSR1SMN1; SMN2ALDH1A1LMNAMAPT
SCHEMBL2685019 0.79 HDAC1 (0.53) ADRB2NPSR1SMN1; SMN2ALDH1A1CYP1A2
SCHEMBL2686332 0.75 ALDH1A1 (0.48) ADRB2NPSR1SMN1; SMN2ALDH1A1LMNA
SCHEMBL2684552 0.75 HDAC1 (0.56) ADRB2NPSR1ALDH1A1ABCB1
SCHEMBL26199245 0.73 MC4R (0.54) ALDH1A1LMNACYP2D6GAAHPGD
SCHEMBL7260049 0.73 CHRM2 (0.54) ADRB2NPSR1SMN1; SMN2ALDH1A1LMNA
SCHEMBL10900898 0.73 OPRD1 (0.59) ADRB2NPSR1SMN1; SMN2ALDH1A1LMNA
SCHEMBL2686534 0.72 NPSR1 (0.46) ADRB2NPSR1SMN1; SMN2ALDH1A1LMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1991226-B1 INHIBITORS OF HISTONE DEACETYLASE MERCK SHARP & DOHME (US) 2013-03-20 EP disclosed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US disclosed
US-8168658-B2 Inhibitors of histone deacetylase MERCK SHARP & DOHME CORP. (US) 2012-05-01 US disclosed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US disclosed
US-20090069250-A1 Inhibitors of Histone Deacetylase MERCK SHARP & DOHME LLC 2009-03-12 US disclosed
WO-2007100657-A2 INHIBITORS OF HISTONE DEACETYLASE MERCK & CO., INC. (US) 2007-09-07 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090069250-A1 Inhibitors of Histone Deacetylase HDAC1, HDAC5, HDAC6 ADRB2 4188/4885NPSR1 2991/4885SMN1; SMN2 406/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.